{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:35Z","timestamp":1792515755246,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017369","name":"Scientific and Technological Planning Project of Guangzhou City","doi-asserted-by":"publisher","award":["2023A03J0211"],"award-info":[{"award-number":["2023A03J0211"]}],"id":[{"id":"10.13039\/100017369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010135"],"award-info":[{"award-number":["2023A1515010135"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515220090"],"award-info":[{"award-number":["2023A1515220090"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010522"],"award-info":[{"award-number":["2023A1515010522"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030313641"],"award-info":[{"award-number":["2018A030313641"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013092","name":"Science and Technology Planning Project of Fuzhou","doi-asserted-by":"publisher","award":["202102010171"],"award-info":[{"award-number":["202102010171"]}],"id":[{"id":"10.13039\/501100013092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116902","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T08:08:44Z","timestamp":1718179724000},"page":"116902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation"],"prefix":"10.1016","volume":"176","author":[{"given":"Xiaorui","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116902_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116902_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver cancer: connections with obesity, fatty liver, and cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu Rev. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ijc.30463","article-title":"Cancer incidence and cancer control in Mongolia: results from the National Cancer Registry 2008-12","volume":"140","author":"Chimed","year":"2017","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib4","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib5","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2024.116902_bib6","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2024.116902_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib10","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116902_bib12","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.7150\/thno.54648","article-title":"Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma","volume":"11","author":"Dai","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2024.116902_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116902_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.116902_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1609575","article-title":"New Insights into the Epigenetics of Hepatocellular Carcinoma","volume":"2017","author":"Wahid","year":"2017","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.biopha.2024.116902_bib16","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180915","article-title":"Non-coding RNA in drug resistance of hepatocellular carcinoma","volume":"38","author":"Ding","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2024.116902_bib17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/hep.29519","article-title":"Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma","volume":"67","author":"Lo Re","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.116902_bib18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41416-020-0823-9","article-title":"Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential","volume":"122","author":"Tsui","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2015.06.009","article-title":"Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.","volume":"63","author":"Nio","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.116902_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ije\/dyr184","article-title":"The epigenotype. 1942","volume":"41","author":"Waddington","year":"2012","journal-title":"Int J. Epidemiol."},{"issue":"Suppl","key":"10.1016\/j.biopha.2024.116902_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ng1089","article-title":"Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals","volume":"33","author":"Jaenisch","year":"2003","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2024.116902_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.74.010904.153721","article-title":"Eukaryotic cytosine methyltransferases","volume":"74","author":"Goll","year":"2005","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.biopha.2024.116902_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/gad.947102","article-title":"DNA methylation patterns and epigenetic memory","volume":"16","author":"Bird","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2024.116902_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/cr500470n","article-title":"TET family proteins: oxidation activity, interacting molecules, and functions in diseases","volume":"115","author":"Lu","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2024.116902_bib28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.biopha.2024.116902_bib29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","article-title":"Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine","volume":"333","author":"Ito","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.biopha.2024.116902_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cell.2011.03.022","article-title":"Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain","volume":"145","author":"Guo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib31","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1021\/ja5019223","article-title":"Direct decarboxylation of 5-carboxylcytosine by DNA C5-methyltransferases","volume":"136","author":"Liutkevi\u010di\u016bt\u0117","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2024.116902_bib32","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1039\/C6CS00599C","article-title":"Epigenetic modification of nucleic acids: from basic studies to medical applications","volume":"46","author":"Chen","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2024.116902_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/278188a0","article-title":"Crystal structure of a eukaryotic initiator tRNA","volume":"278","author":"Schevitz","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0006-3002(61)90668-0","article-title":"The occurrence of 1-methyladenine in ribonucleic acid","volume":"46","author":"Dunn","year":"1961","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.biopha.2024.116902_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molcel.2016.01.012","article-title":"Nuclear m(6)A reader YTHDC1 regulates mRNA splicing","volume":"61","author":"Xiao","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1017\/S1355838299982201","article-title":"Multisite-specific tRNA:m5C-methyltransferase (Trm4) in yeast Saccharomyces cerevisiae: identification of the gene and substrate specificity of the enzyme","volume":"5","author":"Motorin","year":"1999","journal-title":"Rna"},{"key":"10.1016\/j.biopha.2024.116902_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm3785","article-title":"The dynamic epitranscriptome: N6-methyladenosine and gene expression control","volume":"15","author":"Meyer","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nsmb.3162","article-title":"N6-methyladenosine\u2013encoded epitranscriptomics","volume":"23","author":"Liu","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.stem.2015.01.016","article-title":"m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency","volume":"16","author":"Chen","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib40","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/ncomms2822","article-title":"FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA","volume":"4","author":"Fu","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116902_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","article-title":"ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility","volume":"49","author":"Zheng","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.2040","article-title":"Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome.","volume":"12","author":"Li","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib43","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1101\/gad.12.23.3650","article-title":"The essential Gcd10p-Gcd14p nuclear complex is required for 1-methyladenosine modification and maturation of initiator methionyl-tRNA","volume":"12","author":"Anderson","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2024.116902_bib44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/nar\/gkh191","article-title":"A primordial RNA modification enzyme: the case of tRNA (m1A) methyltransferase","volume":"32","author":"Roovers","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116902_bib45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/nar\/gks1102","article-title":"Yeast Rrp8p, a novel methyltransferase responsible for m1A 645 base modification of 25S rRNA","volume":"41","author":"Peifer","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116902_bib46","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/15476286.2014.992278","article-title":"Pseudouridine: still mysterious, but never a fake (uridine)!","volume":"11","author":"Spenkuch","year":"2014","journal-title":"RNA Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib47","doi-asserted-by":"crossref","first-page":"38969","DOI":"10.1074\/jbc.R600034200","article-title":"Substrate recognition by RNA 5-methyluridine methyltransferases and pseudouridine synthases: a structural perspective","volume":"281","author":"Hur","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116902_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","article-title":"The role of m(6)A, m(5)C and \u03a8 RNA modifications in cancer: Novel therapeutic opportunities.","volume":"20","author":"Nombela","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1120976","article-title":"Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2","volume":"311","author":"Goll","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biopha.2024.116902_bib50","doi-asserted-by":"crossref","first-page":"11582","DOI":"10.1021\/ja505305z","article-title":"Tet-mediated formation of 5-hydroxymethylcytosine in RNA","volume":"136","author":"Fu","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2024.116902_bib51","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of rna synthesis","volume":"51","author":"Allfrey","year":"1964","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2024.116902_bib52","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202051803","article-title":"The interplay between DNA and histone methylation: molecular mechanisms and disease implications","volume":"22","author":"Li","year":"2021","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2024.116902_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0092-8674(02)00798-5","article-title":"Histone methylation: dynamic or static?","volume":"109","author":"Bannister","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib54","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S1097-2765(03)00479-9","article-title":"Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains","volume":"12","author":"Rice","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.molcel.2011.08.042","article-title":"NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming","volume":"44","author":"Kuo","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1875397301005010062","article-title":"Chemical biology of lysine demethylases","volume":"5","author":"Heightman","year":"2011","journal-title":"Curr. Chem. Genom."},{"key":"10.1016\/j.biopha.2024.116902_bib58","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026484","article-title":"Histone Lysine Demethylase Inhibitors","volume":"7","author":"Jambhekar","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/PPO.0000000000000283","article-title":"Targeting Histone Methylation in Cancer","volume":"23","author":"McCabe","year":"2017","journal-title":"Cancer J."},{"key":"10.1016\/j.biopha.2024.116902_bib60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2006.03.028","article-title":"Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases","volume":"125","author":"Whetstine","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib61","doi-asserted-by":"crossref","first-page":"55789","DOI":"10.18632\/oncotarget.10048","article-title":"The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target","volume":"7","author":"Di Martile","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116902_bib62","article-title":"Investigation of the acetylation mechanism by GCN5 histone acetyltransferase","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116902_bib63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/bi602513x","article-title":"Catalytic mechanism of a MYST family histone acetyltransferase","volume":"46","author":"Berndsen","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2024.116902_bib64","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1021\/jp409778e","article-title":"Catalytic mechanism of histone acetyltransferase p300: from the proton transfer to acetylation reaction","volume":"118","author":"Zhang","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.biopha.2024.116902_bib65","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein lysine acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2024.116902_bib66","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1868-7083-4-5","article-title":"Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors","volume":"4","author":"Delcuve","year":"2012","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2024.116902_bib68","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/BST20130010","article-title":"The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts","volume":"41","author":"Kelly","year":"2013","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.biopha.2024.116902_bib69","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib70","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.15252\/embj.201797135","article-title":"Modulating NAD(+) metabolism, from bench to bedside","volume":"36","author":"Katsyuba","year":"2017","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2024.116902_bib71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmolb.2020.00021","article-title":"Resolving the Complexity of Ubiquitin Networks","volume":"7","author":"Kliza","year":"2020","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.biopha.2024.116902_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dnarep.2017.06.011","article-title":"Histone ubiquitination in the DNA damage response","volume":"56","author":"Uckelmann","year":"2017","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.biopha.2024.116902_bib73","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.emboj.7600577","article-title":"Histone H3 phosphorylation can promote TBP recruitment through distinct promoter-specific mechanisms","volume":"24","author":"Lo","year":"2005","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2024.116902_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","article-title":"PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis","volume":"150","author":"Yang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib76","first-page":"71","article-title":"MKP1 phosphatase mediates G1-specific dephosphorylation of H3Serine10P in response to DNA damage","volume":"778","author":"Sharma","year":"2015","journal-title":"Mutat. Res"},{"key":"10.1016\/j.biopha.2024.116902_bib77","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cub.2011.03.047","article-title":"PP1\/Repo-man dephosphorylates mitotic histone H3 at T3 and regulates chromosomal aurora B targeting","volume":"21","author":"Qian","year":"2011","journal-title":"Curr. Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3941","article-title":"Histone exchange, chromatin structure and the regulation of transcription","volume":"16","author":"Venkatesh","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib79","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.febslet.2015.05.016","article-title":"A brief review of nucleosome structure","volume":"589","author":"Cutter","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2024.116902_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102986","article-title":"VRK1 phosphorylates Tip60\/KAT5 and is required for H4K16 acetylation in response to DNA damage","volume":"12","author":"Garc\u00eda-Gonz\u00e1lez","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116902_bib81","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tig.2020.12.005","article-title":"Histone Ubiquitination: An Integrative Signaling Platform in Genome Stability","volume":"37","author":"Mattiroli","year":"2021","journal-title":"Trends Genet"},{"key":"10.1016\/j.biopha.2024.116902_bib82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13046-022-02297-2","article-title":"Epigenetic remodelling in human hepatocellular carcinoma","volume":"41","author":"Braghini","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib83","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","article-title":"Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs","volume":"12","author":"Ganten","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gut.2010.208041","article-title":"Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation","volume":"60","author":"Venturelli","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2024.116902_bib85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2407-12-109","article-title":"Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance","volume":"12","author":"Heise","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib86","first-page":"1065","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology","volume":"58","author":"Herraez","year":"2013"},{"key":"10.1016\/j.biopha.2024.116902_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/692071","article-title":"Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology","volume":"2013","author":"Lozano","year":"2013","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.biopha.2024.116902_bib88","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/bph.14563","article-title":"Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib","volume":"176","author":"Al-Abdulla","year":"2019","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2024.116902_bib89","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib90","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13148-020-0821-z","article-title":"DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer","volume":"12","author":"Galle","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2024.116902_bib93","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1096\/fasebj.5.14.1661245","article-title":"Retinoids and their receptors in differentiation, embryogenesis, and neoplasia","volume":"5","author":"De Luca","year":"1991","journal-title":"Faseb J."},{"key":"10.1016\/j.biopha.2024.116902_bib94","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/carcin\/21.7.1271","article-title":"Retinoids in chemoprevention and differentiation therapy","volume":"21","author":"Hansen","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2024.116902_bib95","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1096\/fasebj.10.9.8801176","article-title":"A decade of molecular biology of retinoic acid receptors","volume":"10","author":"Chambon","year":"1996","journal-title":"Faseb J."},{"key":"10.1016\/j.biopha.2024.116902_bib96","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.canlet.2013.02.057","article-title":"Hepatitis C virus Core protein overcomes all-trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-\u03b22 expression via DNA methylation","volume":"335","author":"Lee","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116902_bib97","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbrc.2012.08.038","article-title":"All-trans retinoic acid activates E-cadherin expression via promoter hypomethylation in the human colon carcinoma HCT116 cells","volume":"425","author":"Woo","year":"2012","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2024.116902_bib98","first-page":"1077","article-title":"Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid","volume":"2","author":"Hoffman","year":"1996","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib99","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2024.116902_bib100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","article-title":"PD-1 Blockers","volume":"162","author":"Wolchok","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib101","article-title":"High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer","volume":"10","author":"Ahn","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116902_bib102","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","article-title":"M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.","volume":"81","author":"Qiu","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib103","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13287-020-01814-4","article-title":"METTL1-mediated m(7)G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development.","volume":"11","author":"Deng","year":"2020","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.biopha.2024.116902_bib104","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/bioinformatics\/btaa178","article-title":"m7GHub: deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine (m7G) sites in human","volume":"36","author":"Song","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2024.116902_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.324","article-title":"Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK\/PI3K\/AKT signaling","volume":"7","author":"Zhang","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116902_bib106","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41419-021-03973-5","article-title":"MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma","volume":"12","author":"Xia","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116902_bib107","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.3748\/wjg.v24.i41.4643","article-title":"Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.116902_bib108","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib109","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103181","article-title":"RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy","volume":"39","author":"Lin","year":"2020","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2024.116902_bib110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-019-1080-5","article-title":"CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9\/BRCA1\/DNAJB6\/KLF4\/AKT1 axis in ovarian cancer","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib111","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1111\/cas.14211","article-title":"Tumor-suppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets","volume":"110","author":"Li","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2024.116902_bib112","doi-asserted-by":"crossref","first-page":"9539","DOI":"10.2147\/OTT.S229507","article-title":"circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt\/\u03b2-catenin pathway in hepatocellular carcinoma.","volume":"12","author":"Chen","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2024.116902_bib113","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12943-020-01281-8","article-title":"N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating \u03b2-catenin signaling.","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib114","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/0929867325666180105103637","article-title":"ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma","volume":"26","author":"Ceballos","year":"2019","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.biopha.2024.116902_bib115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/030089161009600115","article-title":"Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies","volume":"96","author":"Sun","year":"2010","journal-title":"Tumori"},{"key":"10.1016\/j.biopha.2024.116902_bib116","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/sj.onc.1206950","article-title":"Transcriptional regulation of ABC drug transporters","volume":"22","author":"Scotto","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.116902_bib117","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/mol.51.6.963","article-title":"DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter","volume":"51","author":"Sundseth","year":"1997","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.116902_bib118","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/MCB.18.7.4377","article-title":"Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y","volume":"18","author":"Jin","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116902_bib120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2017.03.038","article-title":"Targeting KDM1A attenuates Wnt\/\u03b2-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma","volume":"398","author":"Huang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116902_bib121","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib122","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1021\/bi301278t","article-title":"The \u03a9-loop lid domain of phosphoenolpyruvate carboxykinase is essential for catalytic function","volume":"51","author":"Johnson","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2024.116902_bib123","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2016.09.052","article-title":"MOF acetyl transferase regulates transcription and respiration in Mitochondria","volume":"167","author":"Chatterjee","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib124","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2021.06.016","article-title":"Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy","volume":"519","author":"Jing","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116902_bib125","doi-asserted-by":"crossref","first-page":"86168","DOI":"10.18632\/oncotarget.21030","article-title":"In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116902_bib126","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10637-018-0582-0","article-title":"Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy","volume":"36","author":"Cho","year":"2018","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.biopha.2024.116902_bib127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4062\/biomolther.2022.022","article-title":"CKD-581 Downregulates Wnt\/\u03b2-Catenin Pathway by DACT3 Induction in Hematologic Malignancy","volume":"30","author":"Kim","year":"2022","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.biopha.2024.116902_bib128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1186\/s12885-020-07471-3","article-title":"CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma","volume":"20","author":"Chang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib129","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180915","article-title":"Non-coding RNA in drug resistance of hepatocellular carcinoma","volume":"38","author":"Ding","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2024.116902_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081657","article-title":"Polycomb repressor complex 2 in genomic instability and cancer","volume":"18","author":"Veneti","year":"2017","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116902_bib131","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026575","article-title":"Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer","volume":"6","author":"Laugesen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib132","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41419-020-02853-8","article-title":"LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma","volume":"11","author":"Xie","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116902_bib133","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1172\/JCI66024","article-title":"Cancer stem cells in the development of liver cancer","volume":"123","author":"Yamashita","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.116902_bib134","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","article-title":"EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features","volume":"136","author":"Yamashita","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2024.116902_bib135","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1074\/jbc.M111.287037","article-title":"Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment","volume":"287","author":"Pan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116902_bib136","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib137","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib138","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/s41388-018-0203-6","article-title":"LncFZD6 initiates Wnt\/\u03b2-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation","volume":"37","author":"Chen","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.116902_bib139","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/abbs\/gmaa145","article-title":"miR-199b-5p enhances the proliferation of medullary thymic epithelial cells via regulating Wnt signaling by targeting Fzd6","volume":"53","author":"Wang","year":"2021","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.biopha.2024.116902_bib140","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116902_bib141","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.biopha.2024.116902_bib142","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5732\/cjc.011.10344","article-title":"Aberrant promoter CpG methylation and its translational applications in breast cancer","volume":"32","author":"Xiang","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib143","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","article-title":"Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic","volume":"188","author":"Agrawal","year":"2018","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.116902_bib144","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.drudis.2019.08.006","article-title":"DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2024.116902_bib145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/cmdc.201500394","article-title":"Multitarget Drugs: an Epigenetic Epiphany","volume":"11","author":"Ganesan","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2024.116902_bib146","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib147","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-An Overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.biopha.2024.116902_bib148","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/fon-2016-0526","article-title":"Entinostat: a promising treatment option for patients with advanced breast cancer","volume":"13","author":"Connolly","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib149","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3109\/10428194.2016.1160082","article-title":"Use of class I histone deacetylase inhibitor romidepsin in combination regimens","volume":"57","author":"Petrich","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2024.116902_bib150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib151","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.biopha.2024.116902_bib152","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.biopha.2024.116902_bib153","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib154","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embj.201694058","article-title":": A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination","volume":"36","author":"Wang","year":"2017","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2024.116902_bib155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fgene.2018.00493","article-title":"IDH1: Linking Metabolism and Epigenetics","volume":"9","author":"Raineri","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.biopha.2024.116902_bib156","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","article-title":"Oncogenic Activities of IDH1\/2 Mutations: From Epigenetics to Cellular Signaling","volume":"27","author":"L MG","year":"2017","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib157","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib158","first-page":"548","article-title":"[Breast cancer: figures and facts]","volume":"151","author":"Kubista","year":"2001","journal-title":"Wien. Med Woche"},{"key":"10.1016\/j.biopha.2024.116902_bib159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrclinonc.2015.99","article-title":"Challenges in the management of advanced, ER-positive, HER2-negative breast cancer","volume":"12","author":"Hart","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib160","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib161","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Bukowski","year":"2007","journal-title":"Semin Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib162","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjc.6600567","article-title":"First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence","volume":"87","author":"Sandercock","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib163","first-page":"2246","article-title":"Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers","volume":"8","author":"Wei","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib164","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2007.12.017","article-title":"PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment","volume":"109","author":"Barton","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib165","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib166","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib167","first-page":"25","article-title":"Molecular genetics of prostate cancer: clinical translational opportunities","volume":"26","author":"Vecchione","year":"2007","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib168","first-page":"6039","article-title":"Reversal of drug resistance in human tumor xenografts by 2\u2032-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter","volume":"60","author":"Plumb","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116902_bib169","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urolonc.2009.09.015","article-title":"Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemona\u00efve castration-resistant prostate cancer","volume":"29","author":"Sonpavde","year":"2011","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib170","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc3819","article-title":"Poised epigenetic states and acquired drug resistance in cancer","volume":"14","author":"Brown","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2024.116902_bib171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib172","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.116902_bib173","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib174","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116902_bib175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2024.116902_bib176","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.116902_bib177","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116902_bib178","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrd4583","article-title":"HDAC inhibitors still need a home run, despite recent approval","volume":"14","author":"Guha","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2024.116902_bib179","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrm3915","article-title":"Non-histone protein methylation as a regulator of cellular signalling and function","volume":"16","author":"Biggar","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2018.01.010","article-title":"Intratumor heterogeneity in epigenetic patterns","volume":"51","author":"Assenov","year":"2018","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.biopha.2024.116902_bib181","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1038\/onc.2011.611","article-title":"Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling","volume":"31","author":"Zeller","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.116902_bib182","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/gutjnl-2019-320282","article-title":"Liquid biopsy in the clinical management of hepatocellular carcinoma","volume":"69","author":"von Felden","year":"2020","journal-title":"Gut"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:04:10Z","timestamp":1781651050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":182,"alternative-id":["S0753332224007868"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116902","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116902"}}